Loading...
Loading...
Endo Health Solutions Inc.
ENDP announced today that U.S. District Judge Reggie B. Walton, of
the U.S. District Court for the District of Columbia, dismissed the case of
Endo's subsidiary, Endo Pharmaceuticals Inc., against the U.S. Food and Drug
Administration (FDA). Endo Pharmaceuticals argued that FDA failed to meet its
legal obligation to determine in a timely manner whether the original
formulation of OPANA ER was withdrawn from the market for reasons of safety.
The judge ruled against Endo, noting that he believes the FDA has not unduly
delayed making a determination on the matter. The FDA stated that it intends
to make its determination by May 2013.
Endo reformulated OPANA ER to a version designed to be crush-resistant and
launched this reformulated version in March 2012. The ruling by the court now
allows for a generic non-tamper resistant version to enter the market on Jan.
2, 2013.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in